Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

  1. Caterina Nardella1,2,
  2. Zhenbang Chen1,2,
  3. Leonardo Salmena1,2,6,
  4. Arkaitz Carracedo1,2,6,
  5. Andrea Alimonti1,2,
  6. Ainara Egia1,2,
  7. Brett Carver2,3,
  8. William Gerald4,
  9. Carlos Cordon-Cardo2,5, and
  10. Pier Paolo Pandolfi1,2,7
  1. 1 Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA;
  2. 2 Cancer Biology and Genetics Program, Sloan-Kettering Institute, New York, New York 10021, USA;
  3. 3 Department of Surgery, Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA;
  4. 4 Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA;
  5. 5 Department of Pathology, Columbia University, New York, New York 10032, USA
  1. 6 These authors contributed equally to this work.

Abstract

The mammalian target of rapamycin (mTOR) represents a critical signaling crossroad where pathways commonly disrupted in cancer converge. We report here that Rheb GTPase, the upstream activator of the mTOR complex 1 (mTORC1) is amplified in human prostate cancers. We demonstrate that Rheb overexpression promotes hyperplasia and a low-grade neoplastic phenotype in the mouse prostate while eliciting a concomitant senescence response and a negative feedback loop limiting Akt activation. Importantly, we show that Pten haploinsufficiency cooperates with Rheb overexpression to markedly promote prostate tumorigenesis. We conclude that Rheb acts as a proto-oncogene in the appropriate genetic milieu and signaling context.

Keywords

Footnotes

| Table of Contents

Life Science Alliance